ACCESS Newswire
21 Oct 2019, 19:31 GMT+10
WESTLAKE VILLAGE, CA / ACCESSWIRE / October 21, 2019 / Arcutis Biotherapeutics, Inc. ('Arcutis'), a privately held clinical-stage biopharmaceutical company focusing on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that it has completed a $94.5 million Series C financing led by HBM Healthcare Investments. Additional new investors included Vivo Capital, funds and accounts managed by BlackRock, Omega Funds, Pivotal BioVentures, and Goldman Sachs. New investors accounted for more than 50% of the total Series C investment. In addition, existing investors, including Frazier Healthcare Partners, Bain Capital Life Sciences, OrbiMed, and RA Capital Management, provided continued strong support and accounted for the remainder of the Series C proceeds. Since its founding in 2016, Arcutis has raised more than $160 million.
In connection with the financing, Dr. Alexander Asam, Investment Advisor of HBM Partners, has joined Arcutis' Board of Directors. Dr. Asam brings more than 20 years of experience as a global life sciences investor.
Arcutis plans to use the proceeds of the financing to fund Phase 3 clinical development of its lead product candidate ARQ-151, a topical cream formulation containing roflumilast, in plaque psoriasis. In addition, it plans to fund continued development of ARQ-151 in atopic dermatitis. Arcutis currently anticipates reporting topline data for Phase 3 studies in plaque psoriasis in the first half of 2021. Phase 2a topline data in atopic dermatitis is expected by year end 2019.
Frank Watanabe, Arcutis' President and Chief Executive Officer, commented: 'We are delighted to expand our network of impactful and experienced life science investors, including adding Dr. Asam to our Board of Directors, and appreciate the continued strong support of our existing investors. We are excited about the shared commitment to developing dermatology products with the potential to positively impact patients' lives across multiple skin diseases.'
About Arcutis - Bioscience, applied to the skin.
Arcutis is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. Arcutis exploits recent innovations in inflammation and immunology to develop potential best-in-class therapies against validated biological targets, leveraging our deep development, formulation and commercialization expertise to bring to market novel dermatology treatments, while maximizing our probability of technical success and financial resources. Arcutis is currently developing two novel compounds (ARQ-151 and ARQ-252) for multiple indications, including psoriasis, atopic dermatitis and eczema. For more information, please visit www.arcutis.com or follow the Company on LinkedIn.
Contact:
John W. Smither
Chief Financial Officer
[email protected]
Investors and Media:
Derek Cole
720.785.4497
[email protected]
###
SOURCE: Arcutis Biotherapeutics, Inc.
Get a daily dose of Boston Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Boston Star.
More InformationNEW YORK CITY, New York: With just weeks to spare before a potential government default, U.S. lawmakers passed a sweeping tax and spending...
PARIS, France: Fast-fashion giant Shein has been fined 40 million euros by France's antitrust authority over deceptive discount practices...
PALO ALTO/TEL AVIV: The battle for top AI talent has claimed another high-profile casualty—this time at Safe Superintelligence (SSI),...
FRANKLIN, Tennessee: Hundreds of thousands of Nissan and Infiniti vehicles are being recalled across the United States due to a potential...
REDMOND, Washington: Microsoft is the latest tech giant to announce significant job cuts, as the financial strain of building next-generation...
LONDON UK - U.S. stock markets were closed on Friday for Independence Day. Global Forex Markets Wrap Up Friday with Greeback Comeback...
FRANKLIN, Tennessee: Hundreds of thousands of Nissan and Infiniti vehicles are being recalled across the United States due to a potential...
(Photo credit: Mark J. Rebilas-Imagn Images) The Washington Nationals dismissed manager Dave Martinez and general manager Mike Rizzo...
(Photo credit: Rafael Suanes-Imagn Images) Trevor Story and Ceddanne Rafaela each homered to help the visiting Boston Red Sox complete...
(Photo credit: Rafael Suanes-Imagn Images) Trevor Story and Ceddanne Rafaela each homered to help the visiting Boston Red Sox complete...
(Photo credit: Bruce Kluckhohn-Imagn Images) The Washington Wizards completed a three-team trade on Sunday, acquiring guard CJ McCollum,...
(Photo credit: Jayne Kamin-Oncea-Imagn Images) League rebounding leader Angel Reese of the Chicago Sky and assists leader Alyssa...